Flunisolide
Administration
- Type: Inhaled corticosteroid
- Dosage Forms: 80mcg/spray
- Routes of Administration: Inhalation
- Common Trade Names: Aerospan
Adult Dosing
- Inhalation: 2-4 puffs BID
- Max: 640 mcg/day
Pediatric Dosing
- 6-11 yo: 1-2 puffs BID
- Max: 320 mcg/day
- >12 yo: 2-4 puffs BID
- Max: 640 mcg/day
Special Populations
- Pregnancy Rating: D; Possible risk of fetal adrenal suppression; Low risk of teratogenicity
- Lactation risk: L3; Safety unknown
Renal Dosing
- Adult: Not Defined
- Pediatric: Not Defined
Hepatic Dosing
- Adult: Not Defined
- Pediatric: Not Defined
Contraindications
- Allergy to class/drug
- Hypersensitivity to drug/class
- Status asthmaticus
- Asthma, acute
- Avoid abrupt withdrawal
- Bronchospasm, acute
Adverse Reactions
Serious
- Bronchospasm
- Adrenal suppression
- Hypercorticism
- Growth suppression (peds pts)
- Glaucoma
- Cataracts
- Osteoporosis
- erythema multiforme
Common
- URI
- Headache
- Nausea/vomiting
- Dyspepsia
- UTI
- Abdominal pain
- Chest pain
- Infection
- Neck pain
- Diarrhea
- Candidiasis, oral
- Edema
- Myalgia
- Dizziness
- Insomnia
- Voice changes
- Conjunctivitis
- Ear pain
- Taste changes
- Dysmenorrhea
- Vaginitis
Pharmacology
- Half-life: 1.3-1.7 hr
- Metabolism: Liver; CYP450: 3A4 substrate
- Excretion: Urine <1%
Mechanism of Action
Exact mechanism unknown. Inhibits multiple inflammatory cytokines and produces multiple glucocorticoid and mineralocorticoid effects.
See Also
References
This article is issued from
Wikem.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.